Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today

By Joe Tenebruso - Aug 12, 2020 at 12:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions.

What happened

Coronavirus-related stocks declined sharply on Wednesday, extending their losses following Russia's announcement on Tuesday that it had developed the world's first COVID-19 vaccine. 

As of 11:55 a.m. EDT, shares of Novavax (NVAX -0.28%), Heat Biologics (HTBX 1.46%), Sorrento Therapeutics (SRNE 0.54%), Vaxart (VXRT 2.31%), and iBio (IBIO 0.14%) were down 20%, 17%, 15%, 14%, and 14%, respectively.

So what

Russian President Vladimir Putin's statements that Russia was planning to begin a wide-scale immunization program after approving a coronavirus vaccine sent investors into a tizzy. Despite warnings by U.S. and international scientists that Russia's claims regarding its vaccine had not yet been substantiated, many investors decided to sell their shares of COVID-19 vaccine and treatment stocks. That selling appears to be continuing today.

A downward sloping stock chart.

Many coronavirus-focused companies saw their stock prices fall sharply on Wednesday. Image source: Getty Images.

Moderna's (MRNA -0.47%) announcement late on Tuesday that it had struck a $1.5 billion deal with the U.S. government for its COVID-19 vaccine candidate could also be contributing to the declines. Investors in Novavax, Sorrento, Heat Biologics, Vaxart, and iBio may be growing increasingly concerned that, even if Russia's claims prove false, their companies may be falling behind Moderna -- whose stock was up about 1% on Wednesday -- and other competitors in the race for a coronavirus vaccine.

Now what 

Investors have bid up the shares of many companies that are working to develop coronavirus vaccines or treatments in recent months. Unfortunately, many of these companies will not be successful in their efforts. Shareholders appear to be adjusting their views of Sorrento, Vaxart, Novavax, iBio, Heat Biologics, and other vaccine stocks to reflect this reality. In the process, they're assigning them higher risk profiles, and, by extension, lower prices.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$60.10 (-0.28%) $0.17
Heat Biologics, Inc. Stock Quote
Heat Biologics, Inc.
HTBX
$2.78 (1.46%) $0.04
Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.77 (0.54%) $0.01
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$185.97 (-0.47%) $0.87
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$4.21 (2.31%) $0.10
iBio, Inc. Stock Quote
iBio, Inc.
IBIO
$0.28 (0.14%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.